CTP 010

Drug Profile

CTP 010

Alternative Names: CTP-010

Latest Information Update: 27 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Concit Pharma
  • Developer Contera Pharma
  • Class Antiparkinsonians
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase Unknown Drug-induced dyskinesia

Most Recent Events

  • 24 Apr 2013 Investigation in Drug-induced dyskinesia in Denmark (unspecified route)
  • 24 Apr 2013 Concit Pharma plans a phase IIa trial for Drug-induced dyskinesia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top